C8-Ceramide
Based on 1 Customer Validation
C8-Ceramide (N-Octanoyl-D-erythro-sphingosine) is a cell-permeable analog of naturally occurring ceramides. C8-Ceramide has anti-proliferation properties and acts as a potent chemotherapeutic agent. C8-Ceramide stimulates dendritic cells to promote T cell responses upon virus infections. C8-Ceramide induces slight activation of protein kinase (PKC) in vitro.
For research use only. We do not sell to patients.
- Purity: 98.0%
- CAS No.: 74713-59-0
- Formula: C26H51NO3
- Molecular Weight:425.69
-
Storage:
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Epigenetics Compound Library
HY-L005
-
Immunology/Inflammation Compound Library
HY-L007
-
TGF-beta/Smad Compound Library
HY-L018
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Oxygen Sensing Compound Library
HY-L045
-
Cytoskeleton Compound Library
HY-L060
-
Anti-Lung Cancer Compound Library
HY-L075
-
Chemotherapy Drug Library
HY-L112
-
Coagulation and Anti-coagulation Compound Library
HY-L136
-
Membrane Protein-targeted Compound Library
HY-L149
-
Cell Death Library
HY-L162
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
Biological Activity
|
PKC |
apoptosis |
autophagy |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MCF7 | IC50 |
1.2 μM
Compound: C8-cer
|
Antiproliferative activity against tumor necrosis factor-resistant human MCF7 cells after 24 hrs by MTT assay
Antiproliferative activity against tumor necrosis factor-resistant human MCF7 cells after 24 hrs by MTT assay
|
[PMID: 19694470] |
| MCF7 | IC50 |
4.2 μM
Compound: C8-cer
|
Inhibition of clonogenic survival of human MCF7 cells after 10 days by microscopy
Inhibition of clonogenic survival of human MCF7 cells after 10 days by microscopy
|
[PMID: 19694470] |
| MCF7 | IC50 |
4.5 μM
Compound: C8-cer
|
Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
|
[PMID: 19694470] |
| MCF7 | IC50 |
8.6 μM
Compound: C8-cer
|
Inhibition of clonogenic survival of tumor necrosis factor-resistant human MCF7 cells after 10 days by microscopy
Inhibition of clonogenic survival of tumor necrosis factor-resistant human MCF7 cells after 10 days by microscopy
|
[PMID: 19694470] |
| MDA-MB-231 | IC50 |
1.8 μM
Compound: C8-cer
|
Antiproliferative activity against endocrine-resistant human MDA-MB-231 cells after 24 hrs by MTT assay
Antiproliferative activity against endocrine-resistant human MDA-MB-231 cells after 24 hrs by MTT assay
|
[PMID: 19694470] |
| MDA-MB-231 | IC50 |
3 μM
Compound: C8-cer
|
Inhibition of clonogenic survival of endocrine-resistant human MDA-MB-231 cells after 10 days by microscopy
Inhibition of clonogenic survival of endocrine-resistant human MDA-MB-231 cells after 10 days by microscopy
|
[PMID: 19694470] |
C8-ceramide (3 μM; 48 hours) irreversibly reduces tumor-cell proliferation and induces morphological changes[1].
C8-ceramide can induce necrosis-like cell death, but does not induce caspase-dependent cleavage of PARP (biochemical marker of apoptosis) in human cervical tumor cells[1].
C8-ceramide may increase the endogenous ROS level (10-30 µM; 24 hours) by regulating the switch of SOD1 and SOD2, causing the anti-proliferation (10-50 µM; 24 hours), and consequently triggering the apoptosis (10-50 µM; 48 hours) of NSCLC H1299 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CALO cells, INBL cells, HeLa cells
-
Concentration:3 μM
-
Incubation Time:48 hours
-
Result:Markedly reduced the tumor cell number.
-
Cell Line:H1299 cells
-
Concentration:10 µM, 20 µM, 30 µM, 40 µM, 50 µM
-
Incubation Time:24 hours
-
Result:Decreased the rate of cellular proliferation in a dose-dependent manner, with an IC50 of 22.9 µM.
-
Cell Line:H1299 cells
-
Concentration:10 µM, 20 µM, 30 µM, 40 µM, 50 µM
-
Incubation Time:24 hours
-
Result:Caused the G1 arrest.
-
Cell Line:H1299 cells
-
Concentration:10 µM, 20 µM, 30 µM
-
Incubation Time:24 hours, 48 hours
-
Result:Increased the level of cleaved caspase-3.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice, with lymphocytic choriomeningitis virus infected[3]
-
Dosage:0.1 mg/kg
-
Administration:Intranasal administration
-
Result:Increased the CD8+ T cell response to influenza in the lungs.
Chemical Information
-
CAS No. 74713-59-0
-
Appearance Solid
-
Molecular Weight 425.69
-
Formula C26H51NO3
-
Color White to off-white
-
SMILES
CCCCCCCC(N[C@@H](CO)[C@H](O)/C=C/CCCCCCCCCCCCC)=O
-
Synonyms
N-Octanoyl-D-erythro-sphingosine
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Solvent & Solubility
DMSO : ≥ 100 mg/mL (234.91 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Rebeca López-Marure , et al. Ceramide promotes the death of human cervical tumor cells in the absence of biochemical and morphological markers of apoptosis. Biochem Biophys Res Commun. 2002 May 10;293(3):1028-36. [Content Brief]
[2]. Yuli C. Chang, et al. Exogenous C8-Ceramide Induces Apoptosis by Overproduction of ROS and the Switch of Superoxide Dismutases SOD1 to SOD2 in Human Lung Cancer Cells. Int J Mol Sci. 2018 Oct; 19(10): 3010. [Content Brief]
[3]. Curtis J. Pritzl, et al. A ceramide analogue stimulates dendritic cells to promote T cell responses upon virus infections. J Immunol. 2015 May 1; 194(9): 4339-4349. [Content Brief]
[4]. H W Huang, et al. Ceramides modulate protein kinase C activity and perturb the structure of Phosphatidylcholine/Phosphatidylserine bilayers. Biophys J. 1999 Sep; 77(3): 1489-1497. [Content Brief]
[5]. Lan Weiss, et al. Ceramide contributes to pathogenesis and may be targeted for therapy in VCP inclusion body myopathy. Hum Mol Genet. 2021 Jan 7;ddaa248. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3491 mL | 11.7456 mL | 23.4913 mL | 58.7282 mL |
| 5 mM | 0.4698 mL | 2.3491 mL | 4.6983 mL | 11.7456 mL | |
| 10 mM | 0.2349 mL | 1.1746 mL | 2.3491 mL | 5.8728 mL | |
| 15 mM | 0.1566 mL | 0.7830 mL | 1.5661 mL | 3.9152 mL | |
| 20 mM | 0.1175 mL | 0.5873 mL | 1.1746 mL | 2.9364 mL | |
| 25 mM | 0.0940 mL | 0.4698 mL | 0.9397 mL | 2.3491 mL | |
| 30 mM | 0.0783 mL | 0.3915 mL | 0.7830 mL | 1.9576 mL | |
| 40 mM | 0.0587 mL | 0.2936 mL | 0.5873 mL | 1.4682 mL | |
| 50 mM | 0.0470 mL | 0.2349 mL | 0.4698 mL | 1.1746 mL | |
| 60 mM | 0.0392 mL | 0.1958 mL | 0.3915 mL | 0.9788 mL | |
| 80 mM | 0.0294 mL | 0.1468 mL | 0.2936 mL | 0.7341 mL | |
| 100 mM | 0.0235 mL | 0.1175 mL | 0.2349 mL | 0.5873 mL |
C8-Ceramide Related Classifications
HY-108391 Related Classifications
Powered by Bioz